Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE164664 | GEO | 2021/07/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [lenti]

Project description:Identifying resistance mutations in a drug target provides crucial information. Lentiviral transduction creates multiple types of mutations due to the error-prone nature of the HIV-1 reverse transcriptase (RT) and we show this property can be leveraged to identify mutations that confer resistance to targeted anti-cancer drugs, a technique we term “LentiMutate”. First, we improved LentiMutate by making the lentiviral RT more error-prone. Next, we applied this technique to two anti-cancer drugs, imatinib and AMG 510. We find novel deletions in BCR-ABL that confer resistance to BCR-ABL inhibitors and point mutations in the AMG 510 binding pocket or oncogenic non-G12C mutations, in KRAS-G12C or wild-type KRAS, respectively, that confer resistance to AMG 510. LentiMutate may prove highly valuable to clinical and preclinical cancer drug development

2021-07-25 | GSE164663 | GEO

Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [umi]

2021-07-25 | GSE164661 | GEO

Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs

Project description:Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs

| PRJNA691514 | ENA

Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [umi]

Project description:Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [umi]

| PRJNA691523 | ENA

Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [lenti]

Project description:Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [lenti]

| PRJNA691528 | ENA

Replication-incompetent gammaretroviral and lentiviral vector-based insertional mutagenesis screens identify prostate cancer progression genes.

Project description: Not available

| S-EPMC5884640 | biostudies-literature

Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations.

Project description: Not available

| S-EPMC8448967 | biostudies-literature

Lentiviral-driven discovery of cancer drug resistance mutations

Project description:Identifying resistance mutations in a drug target provides crucial information. Lentiviral transduction creates multiple types of mutations due to the error-prone nature of the HIV-1 reverse transcriptase (RT). We optimized and leveraged this property to identify drug resistance mutations, a technique we term LentiMutate. After validating this technique by identifying clinically relevant EGFR resistance mutations, we applied this technique to two additional anti-cancer drugs, imatinib and AMG 510. We find novel deletions in BCR-ABL1 that confer resistance to BCR-ABL1 inhibitors and point mutations in the AMG 510 binding pocket or oncogenic non-G12C mutations, in KRAS-G12C or wild-type KRAS, respectively, that confer resistance to AMG 510. LentiMutate may prove highly valuable to clinical and preclinical cancer drug development.

2021-07-28 | GSE180965 | GEO

Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer.

Project description: Not available

| S-EPMC3589714 | biostudies-literature

Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.

Project description: Not available

| S-EPMC4429698 | biostudies-literature